Asuncion Mejias1, Rosa Rodríguez-Fernández2, Silvia Oliva3, Mark E Peeples4, Octavio Ramilo5. 1. Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Division of Pediatric Infectious Diseases, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio; Departamento de Farmacologia y Pediatria, Facultad de Medicina, Universidad de Malaga, Malaga, Spain. Electronic address: Asuncion.Mejias@nationwidechildrens.org. 2. Department of Pediatrics, Hospital Infantil Gregorio Marañón, Madrid, Spain; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. 3. Division of Pediatric Emergency Medicine and Critical Care, Hospital Regional Universitario de Malaga, Malaga, Spain; Departamento de Farmacologia y Pediatria, Facultad de Medicina, Universidad de Malaga, Malaga, Spain. 4. Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio. 5. Center for Vaccines and Immunity, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, Ohio; Division of Pediatric Infectious Diseases, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
Abstract
OBJECTIVE: The high burden associated with respiratory syncytial virus (RSV) has made the development of RSV vaccine(s) a global health high priority. This review summarizes the journey to an RSV vaccine, the different strategies and challenges associated with the development of preventive strategies for RSV, and the diverse products that are undergoing clinical testing. DATA SOURCES: Studies on RSV biology, immunology, epidemiology, and monoclonal antibodies (mAbs) and vaccines were searched using MEDLINE. We also searched PATH.org and ClinicalTrials.gov for updated information regarding the status of RSV vaccines and mAbs undergoing clinical trials. STUDY SELECTIONS: We selected relevant studies conducted in infants and young children, pregnant women, and elderly population for the prevention of RSV infection. RESULTS: Identification of a safe and immunogenic vaccine has been an important but elusive initiative for more than 60 years for different reasons, including the legacy of formalin-inactivated vaccine, our limited understanding of the immune response to RSV and how it relates to clinical disease severity, or the need for different end points according to the different vaccine platforms. Nevertheless, there are currently 39 vaccines and mAbs under development and 19 undergoing clinical trials. CONCLUSION: Over the past decade, there have been significant advances in our knowledge of RSV molecular and structural biology and in understanding the human immune response to RSV. Despite the barriers, there are several promising mAbs and RSV vaccines undergoing clinical trials that hope to offer protection to the most vulnerable populations.
OBJECTIVE: The high burden associated with respiratory syncytial virus (RSV) has made the development of RSV vaccine(s) a global health high priority. This review summarizes the journey to an RSV vaccine, the different strategies and challenges associated with the development of preventive strategies for RSV, and the diverse products that are undergoing clinical testing. DATA SOURCES: Studies on RSV biology, immunology, epidemiology, and monoclonal antibodies (mAbs) and vaccines were searched using MEDLINE. We also searched PATH.org and ClinicalTrials.gov for updated information regarding the status of RSV vaccines and mAbs undergoing clinical trials. STUDY SELECTIONS: We selected relevant studies conducted in infants and young children, pregnant women, and elderly population for the prevention of RSV infection. RESULTS: Identification of a safe and immunogenic vaccine has been an important but elusive initiative for more than 60 years for different reasons, including the legacy of formalin-inactivated vaccine, our limited understanding of the immune response to RSV and how it relates to clinical disease severity, or the need for different end points according to the different vaccine platforms. Nevertheless, there are currently 39 vaccines and mAbs under development and 19 undergoing clinical trials. CONCLUSION: Over the past decade, there have been significant advances in our knowledge of RSV molecular and structural biology and in understanding the human immune response to RSV. Despite the barriers, there are several promising mAbs and RSV vaccines undergoing clinical trials that hope to offer protection to the most vulnerable populations.
Authors: Matthew K O'Shea; Margaret A K Ryan; Anthony W Hawksworth; Bryan J Alsip; Gregory C Gray Journal: Clin Infect Dis Date: 2005-06-29 Impact factor: 9.079
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Carmen L Larrañaga; Sandra L Ampuero; Vivian F Luchsinger; Flavio A Carrión; Nelson V Aguilar; Pamela R Morales; María Angélica M Palomino; Lorena F Tapia; Luis F Avendaño Journal: Pediatr Infect Dis J Date: 2009-10 Impact factor: 2.129
Authors: Natalie I Mazur; Deborah Higgins; Marta C Nunes; José A Melero; Annefleur C Langedijk; Nicole Horsley; Ursula J Buchholz; Peter J Openshaw; Jason S McLellan; Janet A Englund; Asuncion Mejias; Ruth A Karron; Eric Af Simões; Ivana Knezevic; Octavio Ramilo; Pedro A Piedra; Helen Y Chu; Ann R Falsey; Harish Nair; Leyla Kragten-Tabatabaie; Anne Greenough; Eugenio Baraldi; Nikolaos G Papadopoulos; Johan Vekemans; Fernando P Polack; Mair Powell; Ashish Satav; Edward E Walsh; Renato T Stein; Barney S Graham; Louis J Bont Journal: Lancet Infect Dis Date: 2018-06-18 Impact factor: 25.071
Authors: Anne M Hause; Vasanthi Avadhanula; Maurizio L Maccato; Phillip M Pinell; Nanette Bond; Patricia Santarcangelo; Laura Ferlic-Stark; Xunyan Ye; Obinna Iwuchukwu; Lauren Maurer; Letisha Aideyan; Kelly Dao; Trevor McBride; Pedro A Piedra; Flor M Munoz Journal: Vaccine Date: 2019-05-10 Impact factor: 3.641
Authors: Federico Martinón-Torres; Adolfo García-Sastre; Andrew J Pollard; Carlos Martín; Albert Osterhaus; Shamez N Ladhani; Octavio Ramilo; Jose Gómez Rial; Antonio Salas; F Xavier Bosch; María Martinón-Torres; Michael J Mina; James Cherry Journal: Hum Vaccin Immunother Date: 2021-11-11 Impact factor: 3.452
Authors: Matthew N McCall; Chin-Yi Chu; Lu Wang; Lauren Benoodt; Juilee Thakar; Anthony Corbett; Jeanne Holden-Wiltse; Christopher Slaunwhite; Alex Grier; Steven R Gill; Ann R Falsey; David J Topham; Mary T Caserta; Edward E Walsh; Xing Qiu; Thomas J Mariani Journal: PLoS Comput Biol Date: 2021-12-28 Impact factor: 4.779
Authors: Michaela J Conley; Judith M Short; Andrew M Burns; James Streetley; Joshua Hutchings; Saskia E Bakker; B Joanne Power; Hussain Jaffery; Joanne Haney; Giulia Zanetti; Pablo R Murcia; Murray Stewart; Rachel Fearns; Swetha Vijayakrishnan; David Bhella Journal: EMBO J Date: 2021-12-22 Impact factor: 14.012